{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:49Z","timestamp":1791901369746,"version":"4.3.4"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LEO Foundation","award":["LF16115"],"award-info":[{"award-number":["LF16115"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory condition associated with atherosclerotic cardiovascular disease (CVD). Systemic anti-psoriatic treatments mainly include methotrexate and biological therapies targeting TNF, IL-12\/23 and IL-17A. We profiled plasma proteins from patients with moderate-to-severe psoriasis to explore potential biomarkers of effective systemic treatment and their relationship to CVD. We found that systemically well-treated patients (PASI &lt; 3.0, n = 36) had lower circulating levels of IL-17 pathway proteins compared to untreated patients (PASI &gt; 10, n = 23). Notably, IL-17C and PI3 were decreased with all four examined systemic treatment types. Furthermore, in patients without CVD, we observed strong correlations among IL-17C\/PI3\/PASI (r \u2265 0.82, p \u2264 1.5 \u00d7 10\u221212) pairs or between IL-17A\/PASI (r = 0.72, p = 9.3 \u00d7 10\u22128). In patients with CVD, the IL-17A\/PASI correlation was abolished (r = 0.2, p = 0.24) and the other correlations were decreased, e.g., IL-17C\/PI3 (r = 0.61, p = 4.5 \u00d7 10\u22125). Patients with moderate-to-severe psoriasis and CVD had lower levels of IL-17A compared to those without CVD (normalized protein expression [NPX] 2.02 vs. 2.55, p = 0.013), and lower IL-17A levels (NPX &lt; 2.3) were associated with higher incidence of CVD (OR = 24.5, p = 0.0028, 95% CI 2.1\u20131425.1). As a result, in patients with moderate-to-severe psoriasis, we propose circulating IL-17C and PI3 as potential biomarkers of effective systemic anti-psoriatic treatment, and IL-17A as potential marker of CVD.<\/jats:p>","DOI":"10.3390\/ijms23010555","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T01:15:26Z","timestamp":1641518126000},"page":"555","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis"],"prefix":"10.3390","volume":"23","author":[{"given":"Xing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"},{"name":"Department of Dermatology and Allergy, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-9151","authenticated-orcid":false,"given":"Amanda","family":"Kvist-Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"},{"name":"Department of Dermatology and Allergy, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"McCauley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-535X","authenticated-orcid":false,"given":"Peter Riis","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital\u2014Herlev and Gentofte, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_3","first-page":"3096","article-title":"IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications","volume":"10","author":"Boehncke","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly Effective New Treatments for Psoriasis Target the IL-23\/Type 17 T Cell Autoimmune Axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_5","first-page":"392","article-title":"The possibilities and principles of methotrexate treatment of psoriasis-the updated knowledge","volume":"31","year":"2014","journal-title":"Adv. Dermatol. Allergol.\/Post\u0229py Dermatol. Alergol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years\u2019 experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjd.16560","article-title":"Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73\/AMPK\/mTOR pathway","volume":"179","author":"Yan","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2018.04.005","article-title":"IL-17 Promotes Scar Formation by Inducing Macrophage Infiltration","volume":"188","author":"Zhang","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2020.00341","article-title":"IL-17C\/IL-17RE: Emergence of a Unique Axis in TH17 Biology","volume":"11","author":"Nies","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1016\/S0021-9258(18)77182-2","article-title":"Elafin: An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence","volume":"265","author":"Wiedow","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2011.11.003","article-title":"Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: From epithelium to endothelium","volume":"83","author":"Alam","year":"2012","journal-title":"Biochem. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ijd.14217","article-title":"Serum elafin as a potential inflammatory marker in psoriasis","volume":"58","author":"Elgharib","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","article-title":"Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis","volume":"181","author":"Lowes","year":"2008","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/keaa405","article-title":"Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis","volume":"60","author":"Leijten","year":"2021","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.7150\/thno.31144","article-title":"In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine","volume":"9","author":"Xu","year":"2019","journal-title":"Theranostics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week","volume":"77","author":"Garshick","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential Immunological Links Between Psoriasis and Cardiovascular Disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/eurheartj\/ehr425","article-title":"Psoriasis and atherosclerosis: Two plaques, one syndrome?","volume":"33","author":"Flammer","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"H867","DOI":"10.1152\/ajpheart.00774.2016","article-title":"Psoriasis as a human model of disease to study inflammatory atherogenesis","volume":"312","author":"Harrington","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2133.2008.08780.x","article-title":"Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach","volume":"159","author":"Spah","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","article-title":"The effect of systemic psoriasis therapies on the incidence of myocardial infarction: A cohort study","volume":"165","author":"Abuabara","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-alpha Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Puig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: Subtle and contextual roles","volume":"35","author":"Taleb","year":"2015","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjd.18001","article-title":"Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways","volume":"181","author":"Reich","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1365-2133.2010.10036.x","article-title":"Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy","volume":"163","author":"Johansen","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"H286","DOI":"10.1152\/ajpheart.00479.2002","article-title":"Elafin-overexpressing mice have improved cardiac function after myocardial infarction","volume":"287","author":"Ohta","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/jir.2019.0241","article-title":"Recombinant Human Elafin Ameliorates Chronic Hyperoxia-Induced Lung Injury by Inhibiting Nuclear Factor-Kappa B Signaling in Neonatal Mice","volume":"40","author":"Li","year":"2020","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"158ra144","DOI":"10.1126\/scitranslmed.3004212","article-title":"Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis","volume":"4","author":"Motta","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_44","first-page":"III289","article-title":"Gene transfer of the serine elastase inhibitor elafin protects against vein graft degeneration","volume":"102","author":"Zaidi","year":"2000","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/mt.2014.162","article-title":"A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation","volume":"23","author":"Small","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI5099","article-title":"Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis","volume":"103","author":"Zaidi","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jdv.16126","article-title":"IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema","volume":"34","author":"Lauffer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Sambandam","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm0598-615","article-title":"Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis","volume":"4","author":"Belaaouaj","year":"1998","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biochi.2007.10.009","article-title":"Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions","volume":"90","author":"Korkmaz","year":"2008","journal-title":"Biochimie"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharm. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.biocel.2008.01.004","article-title":"Human neutrophil elastase: Mediator and therapeutic target in atherosclerosis","volume":"40","author":"Henriksen","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/1346-8138.13301","article-title":"Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-alpha level and the efficacy of TNF-inhibitor therapy in psoriasis","volume":"43","author":"Kui","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","article-title":"Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"141","author":"Ballester","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e28669","DOI":"10.2196\/28669","article-title":"Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study","volume":"10","author":"Kaiser","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: The new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Assarsson, E., Lundberg, M., Holmquist, G., Bjorkesten, J., Thorsen, S.B., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., and Edfeldt, G. (2014). Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095192"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","article-title":"Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data","volume":"18","author":"Doncheva","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: New perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: A database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/555\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:44Z","timestamp":1760362004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010555"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010555","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}